Can trifluridine and tipiracil (Lancever) tablets shrink tumors?

Trifluridine and tipiracil (Lonsurf) tablets are a drug combination used to treat metastatic colorectal cancer and gastric cancer. It consists of two active ingredients: trifluridine and tipiracil.

Trifluridine is an inhibitor of nucleoside metabolism, which means it interrupts DNA synthesis required for cancer cell division. Tipiracil blocks the action of thymidine phosphorylase, an enzyme found in many solid tumors. Trifluridine is broken down by thymidine phosphorylase. By preventing trifluridine from being broken down, tipiracil increases its contact with cancer cells, causing further cell damage. Although trifluridine and tipiracil may provide some efficacy, they do not directly shrink tumors. The drug works by controlling and inhibiting tumor growth to extend patient survival.

During treatment, trifluridine and tipiracil will enter the body and affect the DNA synthesis of cancer cells thereby limiting their growth. While this may not result in immediate tumor shrinkage, long-term use of the drug may have an impact on tumor size over time. However, trifluridine and tipiracil are not ideal for all patients. Each patient's situation is unique, so doctors will consider factors such as the patient's specific condition, the characteristics of the tumor and the patient's overall health when determining treatment options.

It is not known whether trifluridine is safe or effective in children. Women should use effective contraception during and for 6 months after the last dose of trifluridine. The most important thing is to have a thorough discussion and consultation with your doctor before starting trifluridine or tipiracil.